MK-6194 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 2 |
97. 潰瘍性大腸炎
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2051210183 | 09/03/2022 | 02/03/2022 | Single Dose Study of MK-6194 in Healthy Japanese Participants | A Single Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-6194 in Healthy Japanese Participants | Ulcerative colitis | - Drug: MK-6194 MK-6194 1-7.5 mg subcutaneously administered in sterile solution form once - Drug: Placebo 5% glucose subcutaneously administered in sterile solution form once | Tanaka Yoshiyuki | NULL | Recruiting | >= 20age old | <= 55age old | Male | 48 | Phase 1 | Japan |
| 2 | NCT04924114 (ClinicalTrials.gov) | October 14, 2021 | 26/2/2021 | A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) | A Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of PT101 in Subjects With Active Ulcerative Colitis | Ulcerative Colitis | Drug: MK-6194;Drug: MK-6194-matching placebo | Merck Sharp & Dohme LLC | NULL | Recruiting | 18 Years | 80 Years | All | 30 | Phase 1 | United States;Georgia;Germany;Hungary;Moldova, Republic of;Poland;Ukraine;United Kingdom |